This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Elan Corporation plc, Biogen Idec.Subset Data from Two Randomized Phase 3 Trials Show TYSABRI(Rm); Significantly Improves Health-Related Quality of Life for Crohn's Disease Patients with Prior Exposure or Inadequate Response to Anti-TNF(Rm); Therapy. Media Release: 1 Jun 2009. Available from: URL: http://www.elan.com
Rights and permissions
About this article
Cite this article
Natalizumab gets an encore in Crohn's disease. Pharmacoecon. Outcomes News 580, 10 (2009). https://doi.org/10.2165/00151234-200905800-00025
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200905800-00025